Valuation dashboard for AEON Biopharma, Inc. (AEON) with P/E N/A, P/B -0.85, EV/EBITDA -0.54 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.26, AEON has negative trailing earnings (P/E not meaningful) and an ROE of 204.18%. Market capitalisation stands at $11M.
Balance sheet quality for AEON: current ratio of 0.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.85 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3.39 |
| vs Current Price | -1419.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AEON | AEON Biopharma, Inc. | $11M | 204.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.26 |
| Market Cap | $11M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | 204.18% |
| Return on Invested Capital | 1699.74% |
| Return on Assets | -924.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · APM · BOLT · CING · CLNN · CLRB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of AEON: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks